TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today opinion article describes a South Asian physician screened for diabetes at a BMI of 23 but denied a GLP-1 weight-loss drug at BMI 26.5, without diabetes. The piece argues that clinical guidance for Asian patients and drug eligibility rules use different BMI thresholds; individual insurer coverage and the practical effect of revised drug labels remain unclear.
A South Asian physician says she was screened for diabetes after her BMI passed 23 but was denied a GLP-1 weight-loss drug at a BMI of 26.5 because she did not meet the eligibility thresholds used by her clinician or insurer. In an October 31 opinion article for MedPage Today, Hamayle Saeed, MD, argues that the episode shows how diabetes screening guidance for Asian Americans can use lower BMI cutoffs than drug-access rules.
Saeed writes that her doctor began diabetes screening in line with the American Diabetes Association’s guidance for Asian Americans, which uses a BMI of 23 as a screening threshold. She says she does not have diabetes and was told she did not qualify for the GLP-1 drug she sought. The article describes the commonly applied eligibility criteria as BMI of 30, or BMI of 27 with at least one weight-related condition.
The article says the mismatch affects more than one patient’s eligibility. Saeed cites research showing diabetes risk can arise at lower BMIs among some Asian populations. In a study of nearly 1.5 million adults in England, the BMI at which South Asian adults reached the diabetes risk associated with a BMI of 30 among white adults was 23.9; for Chinese adults, it was 26.9. Those figures describe risk comparisons in that study, not individual diagnoses or universal treatment cutoffs.
Saeed also points to coverage restrictions. She reports that Medi-Cal stopped covering GLP-1 drugs for weight loss in January and MassHealth followed in July. The article does not establish that those changes caused her personal denial, nor does it give details of the plan or authorization decision in her case. It argues that coverage limits may compound the effect of BMI criteria for people who fall below conventional thresholds.
How BMI Rules Shape Drug Access
The account draws attention to a policy gap: screening for diabetes risk and eligibility for weight-loss medication can rely on different BMI standards. Clinicians may be prompted to test an Asian patient at a lower BMI, while a payer’s authorization form may still use thresholds that leave that patient ineligible without another qualifying condition.
The issue matters to patients and health systems because BMI is a proxy for body composition and disease risk, not a complete measure of either. Saeed cites guidance and studies suggesting that risk thresholds vary across populations. If coverage rules do not reflect the clinical standards used to identify risk, some patients may be evaluated for disease earlier than they can access a medication intended for weight management.
That does not establish that every patient below BMI 30 should receive a GLP-1 drug, or that a lower threshold would be appropriate for every insurer. Drug benefits, clinical indications and individual medical decisions are separate questions. The report’s central point is that the standards are not aligned, and the article calls for greater clarity about which definition of obesity determines access.
Popular right now
Ninja Foodi Smart 6-in-1 Indoor Grill and Air Fryer, 4 Qt, FG551
Ninja NC501 CREAMi XL Deluxe 11-in-1 Ice Cream and Frozen Treat Maker with Two XL Containers
Samsung 85-Inch QN70H Neo QLED 4K Smart TV (2026)
As an affiliate, we earn on qualifying purchases.
Guidelines and Labels in 2026
The article says the World Health Organization set lower BMI action points for Asian populations in 2004, at 23 and 27.5. It also cites the ADA’s 2026 Standards of Care, which it says direct clinicians to confirm excess adiposity using cutoffs appropriate to ethnicity and specifically identify South Asian patients. In June 2026, according to Saeed, the ADA released Asian-specific waist and BMI thresholds for diagnosing obesity.
Saeed argues that drug access rules have not followed those clinical developments. She writes that revised U.S. labels for Wegovy and Zepbound describe use for adults with obesity, or adults with overweight and a weight-related condition, without stating a numerical BMI in the indication. However, she says the familiar 30 and 27 thresholds remain in trial descriptions and payer authorization forms. The article does not include the text of individual insurer policies, so the extent of variation between plans is not specified.
As evidence relevant to lower-BMI treatment, the piece cites the 2025 STEP 11 study in South Korea and Thailand. The trial enrolled participants using a local obesity definition of BMI 25 or higher. Saeed reports that participants receiving semaglutide lost 16% of body weight, compared with 3.1% among those receiving placebo. A post hoc analysis of 68 participants who began below BMI 30 found average weight loss of 17.6% among the 45 who received semaglutide and 4.4% among the 23 who received placebo. The subgroup analysis is not, by itself, a change to U.S. coverage criteria.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5.”
— Hamayle Saeed, MD, in her MedPage Today opinion article
Coverage Rules Still Vary
The article does not identify the insurer or specific prior authorization policy involved in Saeed’s denial, so the reason for that individual decision cannot be independently established from the supplied material. It is also unclear how widely U.S. plans have changed their criteria following the label revisions described in the article, or whether any use of lower ethnic-specific thresholds is accepted in authorization decisions.
The evidence cited includes population-level risk comparisons and a post hoc analysis of a relatively small STEP 11 subgroup. These findings do not settle which patients should receive treatment or what a coverage threshold should be. The supplied report also ends while discussing race-based medical standards, so it does not provide the author’s full argument on how ethnicity-specific BMI criteria should be applied in practice.
Insurers’ Criteria Under Scrutiny
The article does not announce a policy change or give a timetable for one. The next practical development to watch is whether insurers revise prior authorization forms to match current drug-label wording or adopt BMI criteria that account for population-specific clinical guidance. Patients and clinicians will also need clearer explanations of how a diagnosis, a medication’s approved indication and a plan’s coverage rules interact.
For now, Saeed’s report documents a specific account and presents a broader policy argument; it does not establish a nationwide change in eligibility. Further reporting on insurer policies, federal and state coverage decisions, and clinical guidance would clarify whether the gap she describes is changing.
Key Questions
What happened to the physician described in the report?
Hamayle Saeed, MD, writes that she was screened for diabetes under guidance using a BMI threshold of 23 for Asian Americans, but was denied a GLP-1 weight-loss drug at BMI 26.5 because she did not meet the applicable eligibility criteria.
What BMI thresholds does the article describe for GLP-1 eligibility?
The article describes commonly applied criteria as a BMI of 30, or BMI of 27 with at least one weight-related condition. Actual coverage requirements can depend on the drug, insurer and plan.
Why does the article focus on Asian patients?
Saeed cites guidance and research indicating that some Asian populations can face diabetes and other health risks at lower BMIs than white populations. The article argues that screening guidance has taken this into account more than medication authorization rules have.
Did the drug labels change the BMI coverage thresholds?
Saeed says revised Wegovy and Zepbound labels describe eligible patient groups without giving a numerical BMI in the indication, while payer forms may still use the familiar 30 and 27 thresholds. The report does not establish how every insurer interprets the revised labels.
Does the report show that GLP-1 drugs should be prescribed below BMI 30?
No. The article discusses clinical research and argues for population-specific consideration, but it does not establish a universal prescribing rule. Treatment decisions and coverage depend on individual circumstances, clinical guidance and plan policies.
Source: medpagetoday.com
